These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28774410)

  • 41. The role of HBsAg quantification for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
    Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
    J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hepatitis B virus infection: control or cure?].
    Bourlière M; Oules V; Adhoute X
    Rev Prat; 2018 Mar; 68(3):276-282. PubMed ID: 30869285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers.
    Tada T; Kumada T; Toyoda H; Kobayashi N; Akita T; Tanaka J
    J Gastroenterol Hepatol; 2018 Apr; 33(4):918-925. PubMed ID: 28914957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.
    Seto WK; Wong DK; Fung J; Huang FY; Liu KS; Lai CL; Yuen MF
    Clin Microbiol Infect; 2014 Nov; 20(11):1173-80. PubMed ID: 24975365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy.
    Tanaka E; Matsumoto A; Yoshizawa K; Maki N
    Intervirology; 2008; 51 Suppl 1():3-6. PubMed ID: 18544941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
    Sonneveld MJ; Zoutendijk R; Janssen HL
    J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen.
    Nirei K; Kaneko M; Moriyama M; Arakawa Y
    Intervirology; 2000; 43(2):95-101. PubMed ID: 10971127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Viganò M; Mangia G; Lampertico P
    Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Analysis of clinical characteristics and S gene mutation of hepatitis B virus (HBV) in patients with hepatitis B surface antigen RIA negative and HBV DNA positive].
    Sohn YH; Oh HB; Ko SY; Lim YS; Kwon OJ
    Korean J Lab Med; 2009 Jun; 29(3):224-30. PubMed ID: 19571620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HBsAg quantification: useful for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():97-107. PubMed ID: 24373085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
    Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
    J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.
    Hadziyannis E; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):185-95. PubMed ID: 24417264
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus.
    Berke JM; Dehertogh P; Vergauwen K; Van Damme E; Mostmans W; Vandyck K; Pauwels F
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.